HRP20181782T2 - Peptidno cjepivo pcsk9 - Google Patents

Peptidno cjepivo pcsk9 Download PDF

Info

Publication number
HRP20181782T2
HRP20181782T2 HRP20181782TT HRP20181782T HRP20181782T2 HR P20181782 T2 HRP20181782 T2 HR P20181782T2 HR P20181782T T HRP20181782T T HR P20181782TT HR P20181782 T HRP20181782 T HR P20181782T HR P20181782 T2 HRP20181782 T2 HR P20181782T2
Authority
HR
Croatia
Prior art keywords
vaccine
seq
group
peptide
use according
Prior art date
Application number
HRP20181782TT
Other languages
English (en)
Inventor
Sylvia Brunner
Gergana Galabova
Gabriele Winsauer
Erika Bilcikova
Claudia Juno
Pola Linzmayer-Hirt
Birgit Schuh
Günther STAFFLER
Original Assignee
Affiris Cvd Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Cvd Gmbh filed Critical Affiris Cvd Gmbh
Publication of HRP20181782T1 publication Critical patent/HRP20181782T1/hr
Publication of HRP20181782T2 publication Critical patent/HRP20181782T2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6454Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (10)

1. Cjepivo, naznačeno time, da sadrži najmanje jedan peptid odabran iz skupine koju čine SIPWSLERIT (SEQ ID NO: 21), VIPWNLERIL (SEQ ID NO: 55), i SVPWNLERIQ (SEQ ID NO: 60), pri čemu je taj najmanje jedan peptid vezan ili fuzioniran s farmaceutski prihvatljivim nosačem.
2. Cjepivo prema patentnom zahtjevu 1, naznačeno time, da najmanje jedan peptid na svojem N-završetku i/ili C-završetku sadrži najmanje jedan cisteinski ostatak koji je izravno vezan na njih ili je vezan preko međurazdjelnog slijeda.
3. Cjepivo prema patentnom zahtjevu 1 ili 2, naznačeno time, da se kod farmaceutski prihvatljivog nosača radi o proteinskom nosaču.
4. Cjepivo prema patentnom zahtjevu 3, naznačeno time, da je proteinski nosač odabran iz skupine koju čine Keyhole Limpet hemocijanin (KLH), tetanus toksoid (TT), protein D, ili difterijski toksin (DT), poželjno mutirani difterijski toksin, a još poželjnije CRM197.
5. Cjepivo prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da se cjepivo formulira s pomoćnim sredstvom, a poželjno se adsorbira na Alhidrogel.
6. Cjepivo prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da je za uporabu u postupku za liječenje i/ili prevenciju poremećaja koji su prouzročeni hiperlipidemijom, hiperkolesterolemijom i/ili aterosklerozom, posebno za kardiovaskularne bolesti, moždani udar ili periferne vaskularne bolesti.
7. Cjepivo, naznačeno time, da se sastoji od aminokiselinskog slijeda odabranog iz skupine koju čine SIPWSLERIT (SEQ ID NO: 21), VIPWNLERIL (SEQ ID NO: 55), i SVPWNLERIQ (SEQ ID NO: 60).
8. Cjepivo za uporabu prema patentnom zahtjevu 6, naznačeno time, da se peptidi primjenjuju na sisavcu ili na pojedincu u količini od 0,1 ng do 10 mg, poželjno od 0,5 do 500 μg, još poželjnije od 1 do 100 μg, po imunizaciji.
9. Cjepivo za uporabu prema patentnom zahtjevu 6 ili 8, naznačeno time, da se cjepivo primjenjuje između 2 i 10 puta, poželjno između 2 i 7 puta, još poželjnije do 5 puta, a najpoželjnije najviše do 4 puta.
10. Cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 6, 8 ili 9, naznačeno time, da cjepivo sadrži peptide u količini od 0,5 do 500 μg, poželjno od 1 do 100 μg, ili alternativno od 100 fmola do 10 μmola, poželjno od 10 pmola do 1 μmol, posebno od 100 pmola do 100 nmola.
HRP20181782TT 2012-08-29 2013-08-28 Peptidno cjepivo pcsk9 HRP20181782T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12182241.5A EP2703483A1 (en) 2012-08-29 2012-08-29 PCSK9 peptide vaccine
PCT/EP2013/067797 WO2014033158A2 (en) 2012-08-29 2013-08-28 Vaccine
EP13756108.0A EP2890785B1 (en) 2012-08-29 2013-08-28 Pcsk9 peptide vaccine

Publications (2)

Publication Number Publication Date
HRP20181782T1 HRP20181782T1 (hr) 2019-02-08
HRP20181782T2 true HRP20181782T2 (hr) 2024-06-21

Family

ID=46785271

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181782TT HRP20181782T2 (hr) 2012-08-29 2013-08-28 Peptidno cjepivo pcsk9

Country Status (21)

Country Link
US (5) US9533030B2 (hr)
EP (3) EP2703483A1 (hr)
JP (2) JP6298820B2 (hr)
KR (1) KR102101201B1 (hr)
CN (2) CN107837392A (hr)
AR (2) AR092377A1 (hr)
AU (2) AU2013307319B2 (hr)
CA (1) CA2881318C (hr)
CY (1) CY1121067T1 (hr)
DK (1) DK2890785T3 (hr)
ES (1) ES2693572T3 (hr)
HK (1) HK1249859A1 (hr)
HR (1) HRP20181782T2 (hr)
HU (1) HUE040469T2 (hr)
LT (1) LT2890785T (hr)
PL (1) PL2890785T3 (hr)
PT (1) PT2890785T (hr)
SI (1) SI2890785T1 (hr)
TR (1) TR201815497T4 (hr)
TW (1) TWI615148B (hr)
WO (1) WO2014033158A2 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
BR112018008697A2 (pt) * 2015-11-03 2018-10-30 Affiris Ag método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação.
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
KR102401796B1 (ko) * 2017-04-13 2022-05-25 카딜라 핼쓰캐어 리미티드 신규의 펩타이드 기재 pcsk9 백신
CN114672476A (zh) * 2022-01-14 2022-06-28 复旦大学附属中山医院 人pcsk9蛋白的优势构象表位及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) アジュバント含有ワクチン組成物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP3959746B2 (ja) 1995-06-07 2007-08-15 ペプスキャン システムズ ベー.フェー. 改良ペプチド、免疫原性組成物およびワクチンまたは医薬製剤、lhrhホルモンに対する動物の免疫方法、ならびにlhrh縦列反復ペプチドおよびそのワクチンとしての使用
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0971739B1 (en) 1997-04-01 2004-10-06 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7378384B2 (en) 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US20100233177A1 (en) * 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2009221419B2 (en) * 2008-02-01 2013-09-26 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
NZ620441A (en) * 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
EP2450382A1 (de) * 2010-11-04 2012-05-09 Affiris AG Immunogenes Peptid
RS54639B1 (en) * 2011-09-13 2016-08-31 Affiris Ag PCSK9 VACCINE
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine

Also Published As

Publication number Publication date
KR20150047608A (ko) 2015-05-04
EP3409770A3 (en) 2019-01-23
PT2890785T (pt) 2018-11-09
WO2014033158A3 (en) 2014-04-24
EP2703483A1 (en) 2014-03-05
LT2890785T (lt) 2018-10-25
AR092377A1 (es) 2015-04-15
US20240197844A1 (en) 2024-06-20
TWI615148B (zh) 2018-02-21
US11980657B2 (en) 2024-05-14
US10933123B2 (en) 2021-03-02
AU2013307319A1 (en) 2015-01-22
US20170112908A1 (en) 2017-04-27
DK2890785T3 (en) 2018-11-05
JP6298820B2 (ja) 2018-03-20
HK1249859A1 (zh) 2018-11-16
CA2881318A1 (en) 2014-03-06
CY1121067T1 (el) 2019-12-11
SI2890785T1 (sl) 2018-12-31
ES2693572T3 (es) 2018-12-12
PL2890785T3 (pl) 2019-05-31
US20150306191A1 (en) 2015-10-29
EP3409770A2 (en) 2018-12-05
US9999659B2 (en) 2018-06-19
HRP20181782T1 (hr) 2019-02-08
TW201408322A (zh) 2014-03-01
AU2013307319B2 (en) 2018-09-27
US9533030B2 (en) 2017-01-03
CN104685053A (zh) 2015-06-03
WO2014033158A2 (en) 2014-03-06
AU2018278933A1 (en) 2019-01-17
US20180289781A1 (en) 2018-10-11
US20210138048A1 (en) 2021-05-13
AR128395A2 (es) 2024-04-24
CA2881318C (en) 2021-01-05
CN107837392A (zh) 2018-03-27
TR201815497T4 (tr) 2018-11-21
JP2018048177A (ja) 2018-03-29
KR102101201B1 (ko) 2020-04-17
JP2015528453A (ja) 2015-09-28
EP2890785A2 (en) 2015-07-08
CN104685053B (zh) 2017-12-01
EP2890785B1 (en) 2018-08-08
HUE040469T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
HRP20181782T2 (hr) Peptidno cjepivo pcsk9
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
NO20083793L (no) Antistoffer mot amyloid-beta peptid
MX2018011836A (es) Conjugados de anticuerpo farmaco anti-cd70.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
PE20121393A1 (es) Analogo peptidico de oxintomodulina
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NZ612315A (en) Compositions for immunising against staphylococcus aureus
RU2015122368A (ru) Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
IN2014KN01716A (hr)
IN2014KN01714A (hr)
RU2014114506A (ru) Вакцина
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
HK1126856A1 (en) Methods for identifying polypeptide targets
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
RU2016138365A (ru) Pcsk9 вакцины
WO2013021284A3 (en) Anti-il-6 vaccine composition
JP2015528453A5 (hr)